Oxaliplatin may induce cytokine-release syndrome in colorectal cancer patients

Journal of Biological Regulators and Homeostatic Agents

Volumn 16, Issue 2, 2002, Pages 105-109

  Tonini, G ^a   Santini, D ^a   Vincenzi, Bruno ^a   Borzomati, D ^a   Dicuonzo, G ^a   La Cesa, A ^a   Onori, N ^a   Coppola, R ^a  

^a UNIVERSITY CAMPUS BIO MEDICO   (Italy)

Author keywords

Colorectal cancer; Cytokines release syndrome; IL 6; Oxaliplatin; TNF

Indexed keywords

DEXAMETHASONE; INTERLEUKIN 6; OXALIPLATIN; PANTOPRAZOLE; TROPISETRON; TUMOR NECROSIS FACTOR ALPHA; ANTINEOPLASTIC AGENT; CYTOKINE; PLATINUM COMPLEX;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; BLOOD CHEMISTRY; CANCER PATIENT; CHILL; CLINICAL ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; CYTOKINE RELEASE SYNDROME; DIARRHEA; DRUG HYPERSENSITIVITY; DRUG INFUSION; FEMALE; FEVER; HUMAN; HYPOTENSION; MALE; NAUSEA; PATHOGENESIS; PROTEIN BLOOD LEVEL; REMISSION; STATISTICAL SIGNIFICANCE; STEROID THERAPY; SYMPTOMATOLOGY; BLOOD; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; COLORECTAL TUMOR; LIVER TUMOR; LUNG TUMOR; METABOLISM; METASTASIS; MIDDLE AGED; PATHOLOGY; SYNDROME;

ABDOMINAL PAIN; AGED; ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; CYTOKINES; DEXAMETHASONE; DIARRHEA; FEMALE; FEVER; HUMANS; HYPOTENSION; INTERLEUKIN-6; LIVER NEOPLASMS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NAUSEA; ORGANOPLATINUM COMPOUNDS; SYNDROME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0036024035     PISSN: 0393974X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer
2. Oxaliplatin: A new agent for colorectal cancer
3. Integrating oxaliplatin into the management of colorectal cancer
4. Clinical efficacy of oxaliplatin monotherapy: Phase II trials in advanced colorectal cancer
5. Efficacy of oxaliplatin in the treatment of colorectal cancer
6. Safety of oxaliplatin in the treatment of colorectal cancer
7. Randomized multicenter phase II trial of oxaliplatin plus irinotecan versus raltitrexed as first-line treatment in advanced colorectal cancer
8. Oxaliplatin plus raltitrexed in patients with advanced colorectal carcinoma: Results of a Phase I-II trial
9. Integrating the oral fluoropyrimidines into the management of advanced colorectal cancer
10. Idiosyncratic reaction after oxaliplatin infusion
11. Idiosyncratic reaction after oxaliplatin: Circumvention by use of a continuous infusional administration schedule
12. Reaction after oxaliplatin-prevention with corticosteroids?
13. Oxaliplatin-induced fever and release of IL-6
14. Immunohemolitic anemia following oxaliplatin administration
15. Anaphylaxis after oxaliplatin
16. Pulmonary edema and shock after high-dose aracytine-C for lymphoma; possible role of TNF-alpha and PAF
17. Fever, lymphadenopathy, eosinophilia, lymphocytosis, hepatitis, and dermatitis: A severe adverse reaction to minocycline
18. Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8)